No abstract

From 2014–2019, invasive pulmonary aspergillosis complicated 7.2% (0–23.1% in different influenza seasons) of cases of influenza-associated respiratory failure in Edmonton, Alberta. Disease outcomes ranged from survival without therapy to death despite antifungals. Clinician vigilance, longitudinal local surveillance, and refined criteria to identify patients requiring therapy are needed.

ICU-acquired Gram-negative bacteremia is associated with high mortality. Resistance to ciprofloxacin, piperacillin/tazobactam, and carbapenems was common. Coronary artery disease, immune suppression, and inadequate empiric antimicrobial therapy were independently associated with increased mortality.

The increase in bacteraemia observed since 2007 in western and central Canada appears to coincide with the shift of MLST STs. All VRE isolates remained susceptible to daptomycin, linezolid, chloramphenicol and tigecycline.

No abstract

No abstract

In 2002, the world's largest outbreak of neuroinvasive West Nile virus (WNV) disease occurred. Illinois reported 21% of the total cases in the United States, the most among all states. The epidemiology of WNV in Illinois in 2002 was examined to determine factors associated with severe disease and death. A total of 884 cases were identified and there were 66 deaths. The overall attack rate of WNV infection was 7.1 per 100,000 population and this increased with age. The median ages of patients and patients who died were 56 and 78 years, respectively. Among patients who died, 91% were diagnosed with encephalitis and the case-fatality rate for patients with encephalitis was 18.6%. Patients more than 50 years old had a significantly higher risk of being reported with encephalitis (relative risk [RR] = 3.3, 95% confidence interval [CI] = 2.6-4.3%) and death (RR = 22.3, 95% CI = 5.5-90.4%). Clinicians evaluating elderly patients with WNV infection should assess patients closely for progression of disease.

BackgroundConsideration of cost determinants is crucial to inform delivery of public vaccination programs.Objectives to estimate the average total cost of laboratory‐confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs.MethodsStudy utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory‐confirmed influenza patients admitted to hospitals in the Serious Outcomes Surveillance (SOS), Canadian Immunization Research Network (CIRN), from 2010/11 to 2012/13. Unit costs including hospital overheads were linked to inpatient/outpatient resource utilization before and after admissions.ResultsDataset included 2943 adult admissions to 17 SOS Network hospitals and 24 Toronto Invasive Bacterial Disease Network hospitals. Mean age was 69.5 years. Average hospital stay was 10.8 days (95% CI: 10.3, 11.3), general ward stays were 9.4 days (95% CI: 9.0, 9.8), and ICU stays were 9.8 days (95% CI: 8.6, 11.1) for the 14% of patients admitted to the ICU. Average cost per case was $14 612 CAD (95% CI: $13 852, $15 372) including $133 (95% CI: $116, $150) for medical care prior to admission, $14 031 (95% CI: $13 295, $14 768) during initial hospital stay, $447 (95% CI: $271, $624) post‐discharge, including readmission within 30 days.ConclusionThe cost of laboratory‐confirmed influenza was higher than previous estimates, driven mostly by length of stay and analyzing only laboratory‐confirmed influenza cases. The true per‐patient cost of influenza‐related hospitalization has been underestimated, and prevention programs should be evaluated in this context.